O,lead
O,:
ORGANIZATION,genentech inc.
O,,
O,a
O,leading
O,biotechnology
O,company
O,based
O,in
LOCATION,south san francisco
O,,
O,said
O,its
O,limited
O,partners
O,had
O,approved
O,the
O,company
O,'s
O,early
O,buyout
O,of
O,two
O,research
O,partnerships
O,.
O,the
O,partnerships
O,had
O,sponsored
O,the
O,development
O,of
O,three
O,promising
O,drugs
O,-
O,growth
O,hormone
O,,
O,interferon
O,and
O,a
O,blood
O,clot
ORGANIZATION,dissolver.genentech inc.
O,,
O,a
O,leading
O,biotechnology
O,company
O,based
O,in
LOCATION,south san francisco
O,,
O,said
O,its
O,limited
O,partners
O,had
O,approved
O,the
O,company
O,'s
O,early
O,buyout
O,of
O,two
O,research
O,partnerships
O,.
O,the
O,partnerships
O,had
O,sponsored
O,the
O,development
O,of
O,three
O,promising
O,drugs
O,-
O,growth
O,hormone
O,,
O,interferon
O,and
O,a
O,blood
O,clot
O,dissolver
O,.
O,the
O,buyback
O,,
O,which
O,will
O,cost
ORGANIZATION,genentech
O,more
O,than
O,$
O,400
O,million
O,,
O,received
O,a
O,majority
O,vote
O,despite
O,the
O,opposition
O,of
O,two
O,partners
O,who
O,argued
O,that
O,the
O,original
O,agreement
O,,
O,which
O,would
O,pay
O,them
O,a
O,royalty
O,on
O,sales
O,,
O,was
O,worth
O,more.company
O,news
